Trial Profile
A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant Recipients
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 Mar 2021
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Bronchiolitis obliterans
- Focus Therapeutic Use
- Acronyms EPOS
- 25 Apr 2020 Trial design, presented at the 40th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
- 16 Jan 2020 Status changed from active, no longer recruiting to completed.
- 26 Aug 2019 Planned End Date changed from 1 Oct 2019 to 1 Dec 2019.